Jan. 12, 2020: BioCryst Pharmaceuticals, Inc. announced that the company will provide updates on berotralstat, an oral kallikrein inhibitor for hereditary angioedema (HAE), and BCX9930, an oral Factor D inhibitor for complement-mediated diseases, this week at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
“BioCryst is located for transformation in 2020 with the multiple global approvals and launches of the berotralstat, and PNH proof of the concept data with BCX9930.
The $100 million in additional capital we brought into the company in Q4 2019 provides a foundation for progress and value creation in 2020.”
As formerly announced, results from an ongoing three part Phase 1 trial of BCX9930 showed rapid, sustained and >95% suppression of the alternative pathway (AP) of the complement system at 100 mg every 12 hours, as calculated by the AP Wieslab® assay.
In two initial multiple ascending dose (MAD) assessment cohorts, healthy volunteers inward 50 mg or 100 mg of oral BCX9930 or placebo (each MAD cohort randomized 10:2) administered every 12 hours for seven days.
Healthy volunteers in the MAD cohorts were prophylactically dosed with broad-spectrum antibiotic, amoxicillin/clavulanate. https://fda.einnews.com/pr_news/507012970/biocryst-to-provide-berotralstat-and-bcx9930-program-updates-at-38th-annual-j-p-morgan-healthcare-conference
